Is Can Fite Biopharma Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NYSEMKT: CANF) stock is to Buy CANF stock.
Out of 1 analyst, 0 (0%) are recommending CANF as a Strong Buy, 1 (100%) are recommending CANF as a Buy, 0 (0%) are recommending CANF as a Hold, 0 (0%) are recommending CANF as a Sell, and 0 (0%) are recommending CANF as a Strong Sell.
According to 1 Wall Street analyst that have issued a 1 year CANF price target, the average CANF price target is $34.00, with the highest CANF stock price forecast at $34.00 and the lowest CANF stock price forecast at $34.00.
The Wall Street analyst predicted that Can Fite Biopharma's share price could reach $34.00 by Mar 13, 2024. The average Can Fite Biopharma stock price prediction forecasts a potential upside of 1,452.51% from the current CANF share price of $2.19.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.